Nasic (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride, the active ingredient in Nasic, is a topical nasal decongestant presented as a nasal spray for nasal use. It relieves nasal congestion associated with the common cold, sinusitis, and allergic rhinitis in adults and children when used as directed. It is available over‑the‑counter in many European Union countries and is formulated for rapid onset of action.

GNH USA supplies Nasic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to global quality standards and provides reliable sourcing for regulated markets.

Nasic, a topical alpha‑adrenergic nasal decongestant, acts on swollen nasal mucosa to improve airflow.

- Common cold: reduces nasal blockage and improves breathing. - Sinusitis: alleviates mucosal edema and eases sinus drainage. - Allergic rhinitis: diminishes congestion caused by allergic inflammation.

Nasic may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of the nasal mucosa. - Sneezing or mild epistaxis. - Headache. - Transient taste disturbance.

Serious or Rare Side Effects: - Rebound nasal congestion (rhinitis medicamentosa) after prolonged use. - Elevated blood pressure or tachycardia. - Severe allergic reaction such as anaphylaxis.

Before using Nasic, consider the following safety measures.

- Limit use to 3‑5 days: prolonged use may cause rebound congestion. - Avoid in patients with severe hypertension: may increase blood pressure. - Use with caution in cardiovascular disease: monitor for tachycardia. - Do not use in infants under 2 years: safety not established. - Pregnancy and breastfeeding: consult a healthcare professional before use. - Store at room temperature: keep in the original container, protect from moisture and heat.

Nasic can interact with other medicines that affect blood pressure or sympathetic activity.

Major Interactions (Avoid): - Other nasal decongestants (e.g., phenylephrine): risk of excessive vasoconstriction. - Monoamine oxidase inhibitors (MAOIs): may potentiate hypertensive effects.

Moderate Interactions (Monitor Closely):\n- Systemic sympathomimetics (e.g., pseudoephedrine): additive cardiovascular stimulation. - Antihypertensive drugs: possible reduction in antihypertensive efficacy. - Beta‑blockers: may mask tachycardia signs.